InFocus: Life Sciences & Healthcare e-newsletter - July 2011

Welcome to the July issue of InFocus, our life sciences and healthcare e-newsletter. In this issue we look at:

Features

Inspection proceedings in Germany: Update
Düsseldorf Higher Regional Court decides that "urgency" is not required
Project Atlas: Reckitt Benckiser now shouldering the burden of past behaviour
Since April, further details on the follow on damages claim against Reckitt Benckiser ("RB") have emerged
Commission misses an opportunity in the fight against counterfeits
The proposed new EU regulation on customs enforcement of intellectual property rights
Securing border protection for intellectual property rights in China
More and more IPR holders use the mechanism of border protection in China as a first line of defense to stop the flow of counterfeits into the global market

Case law updates

Advocate General says yes to negative and zero term SPCs
(Case C-125/10)
Clause with teeth: Rights of first refusal and liabiity caps
[2010] EWHC 1028 (Comm)
Open offers: Navigating the Part 36 minefield
[2011] EWCA Civ 646

Hot topics

EU pharmaceutical sector inquiry: European Commission opens investigation into Teva and Cephalon
EU pharmaceutical sector inquiry: EU Commission publishes second report on monitoring patent settlements
Pharma and social media: A review of the pitfalls and the latest guidance
UK clinical trials: Informal consultation on the UK bolar and research exemptions
UK corporate tax reform: HM Treasury consults further on the Patent Box and R&D tax credits
UK corporate tax reform: The CFC consultation - the latest step on the road to reform
EU Patent and unified patent litigation system: Update July 2011
Patent litigation procedure and practice across 30 European jurisdictions
The Bribery Act 2010: How will it impact the pharmaceutical industry?
Pharmaceutical, biotechnology and chemical inventions: World protection and exploitation
Taylor Wessing's Global Intellectual Property Index: The third report

Site Navigation: